Tarsus Pharmaceuticals, Inc. Common Stock TARS
i
Market dataready · fetched 2026-11-03T23:05:15.593Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-03T21:11:42.253406928Z
FundamentalsSEC EDGAR · ready · as of 2026-09-30 · fetched 2026-11-03T23:05:15.150594+00:00
Tarsus Pharmaceuticals, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 104.41 | 164.5% | 47.2% | 61.70 | 105.3% | 17.9% |
| 25Δ | 89.38 | 118.8% | 26.4% | 64.62 | 96.0% | 14.5% |
| 30Δ | 82.69 | 94.6% | 17.4% | 66.72 | 94.9% | 12.5% |
| 35Δ | 79.21 | 83.3% | 13.0% | 68.68 | 92.2% | 10.7% |
| 40Δ | 77.75 | 88.5% | 12.0% | 70.60 | 88.6% | 8.9% |
| 45Δ | 75.70 | 83.7% | 9.8% | 72.35 | 89.4% | 7.8% |
| 50Δ | 73.91 | 83.2% | 8.3% | 74.17 | 90.4% | 6.8% |
| 55Δ | 72.32 | 84.8% | 7.2% | 76.09 | 91.7% | 5.8% |
| 60Δ | 70.74 | 79.9% | 5.7% | 78.19 | 93.7% | 5.0% |
| 65Δ | 69.16 | 77.6% | 4.5% | 80.46 | 95.5% | 4.2% |
| 70Δ | 67.58 | 77.6% | 3.7% | 82.51 | 93.3% | 3.3% |
| 75Δ | 65.87 | 77.5% | 2.9% | 85.00 | 93.0% | 2.5% |
| 80Δ | 63.56 | 82.6% | 2.3% | 88.10 | 93.9% | 1.9% |
20Δ
- Pseudo strike
- 104.41
- IV
- 164.5%
- B/E move
- 47.2%
- Pseudo strike
- 61.70
- IV
- 105.3%
- B/E move
- 17.9%
25Δ
- Pseudo strike
- 89.38
- IV
- 118.8%
- B/E move
- 26.4%
- Pseudo strike
- 64.62
- IV
- 96.0%
- B/E move
- 14.5%
30Δ
- Pseudo strike
- 82.69
- IV
- 94.6%
- B/E move
- 17.4%
- Pseudo strike
- 66.72
- IV
- 94.9%
- B/E move
- 12.5%
35Δ
- Pseudo strike
- 79.21
- IV
- 83.3%
- B/E move
- 13.0%
- Pseudo strike
- 68.68
- IV
- 92.2%
- B/E move
- 10.7%
40Δ
- Pseudo strike
- 77.75
- IV
- 88.5%
- B/E move
- 12.0%
- Pseudo strike
- 70.60
- IV
- 88.6%
- B/E move
- 8.9%
45Δ
- Pseudo strike
- 75.70
- IV
- 83.7%
- B/E move
- 9.8%
- Pseudo strike
- 72.35
- IV
- 89.4%
- B/E move
- 7.8%
50Δ
- Pseudo strike
- 73.91
- IV
- 83.2%
- B/E move
- 8.3%
- Pseudo strike
- 74.17
- IV
- 90.4%
- B/E move
- 6.8%
55Δ
- Pseudo strike
- 72.32
- IV
- 84.8%
- B/E move
- 7.2%
- Pseudo strike
- 76.09
- IV
- 91.7%
- B/E move
- 5.8%
60Δ
- Pseudo strike
- 70.74
- IV
- 79.9%
- B/E move
- 5.7%
- Pseudo strike
- 78.19
- IV
- 93.7%
- B/E move
- 5.0%
65Δ
- Pseudo strike
- 69.16
- IV
- 77.6%
- B/E move
- 4.5%
- Pseudo strike
- 80.46
- IV
- 95.5%
- B/E move
- 4.2%
70Δ
- Pseudo strike
- 67.58
- IV
- 77.6%
- B/E move
- 3.7%
- Pseudo strike
- 82.51
- IV
- 93.3%
- B/E move
- 3.3%
75Δ
- Pseudo strike
- 65.87
- IV
- 77.5%
- B/E move
- 2.9%
- Pseudo strike
- 85.00
- IV
- 93.0%
- B/E move
- 2.5%
80Δ
- Pseudo strike
- 63.56
- IV
- 82.6%
- B/E move
- 2.3%
- Pseudo strike
- 88.10
- IV
- 93.9%
- B/E move
- 1.9%
Options history
Table
| Date | IV (%) |
|---|---|
| 62.26% | |
| 62.87% | |
| 63.02% | |
| 64.15% | |
| 65.34% | |
| 66.42% | |
| 66.00% | |
| 66.80% | |
| 66.76% | |
| 69.65% |
Biotechnology
TECH
Bio-Techne Corporation develops, manufactures, and sells life science reagents, instruments, and services for the global clinical diagnostic and research markets. The company is…
More →TECX
Tectonic Therapeutic, Inc. engages in the discovery of antibodies and other biologic drugs targeting G-protein-coupled receptors (GPCRs) to develop novel therapies for patients…
More →TENX
Tenax Therapeutics, Inc., a specialty pharmaceutical company, is dedicated to identifying, developing, and marketing products for cardiovascular and pulmonary disease in the…
More →TGTX
TG Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and…
More →TNGX
Tango Therapeutics Inc. is a leading clinical-stage biotechnology firm at the forefront of cancer treatment innovation, specializing in synthetic lethality and targeted therapies.…
More →TNXP
Description unavailable
More →